Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy

T cells have been established as core effectors for cancer therapy; this has moved the focus of therapeutic endeavors to effectively enhance or restore T cell tumoricidal activity rather than directly target cancer cells. Both antibodies targeting the checkpoint inhibitory molecules programmed death...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobold, Sebastian, Pantelyushin, Stanislav, Rataj, Felicitas, vom Berg, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068270/
https://www.ncbi.nlm.nih.gov/pubmed/30090763
http://dx.doi.org/10.3389/fonc.2018.00285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068270/
https://www.ncbi.nlm.nih.gov/pubmed/30090763
http://dx.doi.org/10.3389/fonc.2018.00285

Ejemplares similares